Abstract
Patients with atrial fibrillation (AF) require oral anticoagulation to prevent ischemic stroke. However, oral anticoagulation may cause bleeding, and patients with AF and a history of bleeding were excluded from pivotal trials comparing non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin. We therefore aimed to assess the efficacy and safety of NOACs compared with warfarin in patients with AF and a history of bleeding. We conducted a systematic review of retrospective studies and clinical trials using the PubMed, EMBASE, SCOPUS, Cochrane Library, and Web of Science databases to May 2021. Overall, 56,697 patients from six studies were included. NOACs significantly reduced the risk of ischemic stroke (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.59-0.91; p=0.005), fatal ischemic stroke (HR 0.49, 95% CI 0.39-0.61; p<0.001), all-cause mortality (HR 0.70, 95% CI 0.50-0.98; p=0.04), major bleeding events (HR 0.75, 95% CI 0.67-0.84; p<0.001), intracranial hemorrhage (ICH; HR 0.63, 95% CI 0.48-0.82; p<0.001), fatal ICH (HR 0.33, 95% CI 0.20-0.56, p<0.001), and gastrointestinal bleeding (HR 0.83, 95% CI 0.72-0.96; p=0.01). NOACs showed better efficacy and safety profile compared with warfarin in patients with AF and a history of bleeding. Randomized controlled trials are warranted to validate these findings.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: American journal of cardiovascular drugs : drugs, devices, and other interventions
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.